Literature DB >> 12902164

Transcriptional mechanisms in osteoblast differentiation and bone formation.

Kazuhisa Nakashima1, Benoit de Crombrugghe.   

Abstract

Osteoblasts, the cells responsible for bone formation, differentiate from mesenchymal cells. Here, we discuss transcription factors that are involved in regulating the multistep molecular pathway of osteoblast differentiation. Runx2 and Osx, a newly identified zinc-finger-containing protein, are transcription factors that are expressed selectively and at high levels in osteoblasts. Null mutations of either leads to a complete absence of bone in mice. Runx2 plus its companion subunit Cbf beta are needed for an early step in this pathway, whereas Osx is required for a subsequent step, namely the differentiation of preosteoblasts into fully functioning osteoblasts. The finding that Osx-null cells acquire a chondrocyte phenotype implies that Osx is a negative regulator of Sox9 and of the chondrocyte phenotype. This leads to the hypothesis that Osx might have a role in the segregation of osteoblasts from osteochondroprogenitors. We also discuss recent progress in studies of other transcription factors that affect skeletal patterning and development.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12902164     DOI: 10.1016/S0168-9525(03)00176-8

Source DB:  PubMed          Journal:  Trends Genet        ISSN: 0168-9525            Impact factor:   11.639


  126 in total

1.  Bone acquisition in healthy young females is reciprocally related to marrow adiposity.

Authors:  Natascia Di Iorgi; Ashley O Mo; Kate Grimm; Tishya A L Wren; Frederick Dorey; Vicente Gilsanz
Journal:  J Clin Endocrinol Metab       Date:  2010-04-14       Impact factor: 5.958

2.  Expression of master regulatory genes controlling skeletal development in benign cartilage and bone forming tumors.

Authors:  Jane Y Dancer; Stephen P Henry; Jolanta Bondaruk; Sangkyou Lee; Alberto G Ayala; Benoit de Crombrugghe; Bogdan Czerniak
Journal:  Hum Pathol       Date:  2010-12       Impact factor: 3.466

3.  Dynamic expression of Runx2, Osterix and AJ18 in the femoral head of steroid-induced osteonecrosis in rats.

Authors:  Xin-Long Ma; Ze-Peng Liu; Jian-Xiong Ma; Chao Han; Jia-Cheng Zang
Journal:  Orthop Surg       Date:  2010-11       Impact factor: 2.071

4.  Dominance of SOX9 function over RUNX2 during skeletogenesis.

Authors:  Guang Zhou; Qiping Zheng; Feyza Engin; Elda Munivez; Yuqing Chen; Eiman Sebald; Deborah Krakow; Brendan Lee
Journal:  Proc Natl Acad Sci U S A       Date:  2006-12-01       Impact factor: 11.205

5.  Runx3 negatively regulates Osterix expression in dental pulp cells.

Authors:  Li Zheng; Koichiro Iohara; Masaki Ishikawa; Takeshi Into; Teruko Takano-Yamamoto; Kenji Matsushita; Misako Nakashima
Journal:  Biochem J       Date:  2007-07-01       Impact factor: 3.857

6.  Fibroblast growth factor expression during skeletal fracture healing in mice.

Authors:  Gregory J Schmid; Chikashi Kobayashi; Linda J Sandell; David M Ornitz
Journal:  Dev Dyn       Date:  2009-03       Impact factor: 3.780

7.  Effects of three-dimensional spheroid culture on equine mesenchymal stem cell plasticity.

Authors:  Mi Jeong Park; Jienny Lee; Jeong Su Byeon; Da-Un Jeong; Na-Yeon Gu; In-Soo Cho; Sang-Ho Cha
Journal:  Vet Res Commun       Date:  2018-05-02       Impact factor: 2.459

8.  Transgenic mice expressing a ligand-inducible cre recombinase in osteoblasts and odontoblasts: a new tool to examine physiology and disease of postnatal bone and tooth.

Authors:  Jung-Eun Kim; Kazuhisa Nakashima; Benoit de Crombrugghe
Journal:  Am J Pathol       Date:  2004-12       Impact factor: 4.307

Review 9.  Genetic and molecular control of osterix in skeletal formation.

Authors:  Krishna M Sinha; Xin Zhou
Journal:  J Cell Biochem       Date:  2013-05       Impact factor: 4.429

10.  Reciprocal relation between marrow adiposity and the amount of bone in the axial and appendicular skeleton of young adults.

Authors:  Natascia Di Iorgi; Michael Rosol; Steven D Mittelman; Vicente Gilsanz
Journal:  J Clin Endocrinol Metab       Date:  2008-04-01       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.